Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 13/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 11/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 4/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 3/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 2/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.60 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.60 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.60 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamapimod SCHEMBL29429421 | 1.00 | MAPK14 (1.00) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| Pamapimod SCHEMBL3636701 | 1.00 | MAPK14 (1.00) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239772 | 0.96 | MAPK14 (0.93) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL14014670 | 0.90 | MAPK14 (0.88) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239781 | 0.90 | MAPK14 (0.82) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239775 | 0.88 | MAPK14 (0.84) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239778 | 0.88 | MAPK14 (0.84) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2944570 | 0.87 | MAPK14 (0.77) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL2944573 | 0.87 | MAPK14 (0.77) | MAPK14MAPK8MAPK11MAPK9MAPK10 | |
| SCHEMBL13239789 | 0.86 | MAPK14 (1.00) | MAPK14MAPK8MAPK11MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| EP-4587558-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | Fate Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| CN-119948152-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119372130-A | Culture medium for stem cells | 荷兰皇家科学院 | 2025-01-28 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024243567-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-11576916-B2 | Methods of preventing or treating ophthalmic diseases | KINARUS AG (CH) | 2023-02-14 | — | — | US | claimed |
| WO-2023280911-A1 | P38-INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS AND/OR COVID-19 CYTOKINE STORM | Westfälische Wilhelms-Universität Münster (DE) | 2023-01-12 | — | — | WO | claimed |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | UNIVERSITÉ PARIS CITÉ (FR) | 2022-09-29 | — | — | US | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-20220175786-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | SUPPORT-VENTURE GMBH (CH) | 2022-06-09 | — | — | US | claimed |
| EP-3980012-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-04-13 | — | — | EP | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| US-11285155-B2 | Pharmaceutical combinations for treating cancer | SUPPORT-VENTURE GMBH (CH) | 2022-03-29 | — | — | US | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| WO-2022034031-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2022-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285155-B2 | Pharmaceutical combinations for treating cancer | PPARG, PPARA, PPARD | MAPK14 81/4885MAPK8 13/4885MAPK11 33/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885MAPK8 3173/4885MAPK11 1894/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAPK14 14/4885MAPK8 25/4885MAPK11 55/4885 |
| US-11576916-B2 | Methods of preventing or treating ophthalmic diseases | PPARA, PPARG, PPARD | MAPK14 119/4885MAPK8 20/4885MAPK11 55/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | MAPK14 3891/4885MAPK8 2386/4885MAPK11 2811/4885 |
| US-20220175786-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | PPARG, PPARA, PPARD | MAPK14 81/4885MAPK8 13/4885MAPK11 33/4885 |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | NRP1, MAPK1, MAPKAP1 | MAPK14 97/4885MAPK8 19/4885MAPK11 175/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK8 16/4885MAPK11 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.